Oncology Nursing Society

CURE Media Group and Oncology Nursing News Announces the 2024 Extraordinary Healer® Award Finalists

Retrieved on: 
Friday, March 15, 2024
RN, Health, Washington Convention Center, Haematopoietic system, Mentorship, Oncology Nursing Society, Environment, Simmons University, Caregiver, Dana–Farber Cancer Institute, Education, Patient, Research, Transport, Cancer, Wonders, Texas Oncology, Survivor, OSN, Pediatrics, Johnson & Johnson, Media Group, Kidney, Multimedia, Ochsner Health System, Nursing, OCN

This award honors oncology nurses whose compassion and expertise improve the lives of their patients.

Key Points: 
  • This award honors oncology nurses whose compassion and expertise improve the lives of their patients.
  • The award presentations and winner announcement will be held on April 24, 2024 during the Oncology Nursing Society's Annual Congress at The Walter E. Washington Convention Center in Washington, DC.
  • The finalists for the 2024 Extraordinary Healer award are:
    Jessica McDade, B.S.N., RN, OCN.
  • For more information on the 2024 Extraordinary Healer event and to register, please visit the event page .

ChemoMouthpiece, LLC. Announces the Awarding of the 510(k) Marketing Clearance by the FDA for their Oncology Supportive Care Device and Recent Closing of their Private Placement Round

Retrieved on: 
Thursday, February 22, 2024
Vasoconstriction, Incidence, Marketing, ONS, Oncology Nursing Society, Multimedia, ASCO, FDA, News, Pain, Hodgkin lymphoma, Cryotherapy, Nausea, Manuscript, Risk, Mouth, Society, Wastewater treatment, Patient, Chemotherapy, Clinical trial, Lymphoma, Mucositis, Dentistry

announces the FDA 510(k) Marketing Clearance for their device, The Chemo Mouthpiece™.

Key Points: 
  • announces the FDA 510(k) Marketing Clearance for their device, The Chemo Mouthpiece™.
  • has just closed on their Private Placement Round of $10 million in upfront capital with a full commitment for the second tranche of additional funds in excess of $10 million.
  • "Chemo Mouthpiece™ is fully stocked, as we will begin shipping across the US within the next quarter now that we have FDA Marketing Clearance.
  • ChemoMouthpiece, LLC is a privately held medical device company that develops and commercializes propriety oral cryotherapy products for cancer patients.

Cancer Drug Parity Act Gains Strong Support from Leading Healthcare Organizations

Retrieved on: 
Wednesday, November 8, 2023
EBP, Insurance, Attention, ONS, Act, AIM, Public policy, International Myeloma Foundation, IV, Congress, House, Legislation, Face, IMF, RN, Multiple myeloma, CLL, AIM at Melanoma Foundation, Disease, Melanoma, DNP, ACS, Representative, Parity, Oncology Nursing Society, Association of American Cancer Institutes, Cancer, American Cancer Society Cancer Action Network, Oral cancer, Patient, ASCO, Lymphoma, Health insurance, Pharmaceutical industry, Nursing, Dietary supplement

The International Myeloma Foundation (IMF), which leads the Coalition to Improve Access to Cancer Care (CIACC), fervently supports the Cancer Drug Parity Act, recognizing its profound impact on myeloma patients and their families.

Key Points: 
  • The International Myeloma Foundation (IMF), which leads the Coalition to Improve Access to Cancer Care (CIACC), fervently supports the Cancer Drug Parity Act, recognizing its profound impact on myeloma patients and their families.
  • The Cancer Drug Parity Act would put the needs of patients first to ensure that patients, along with their healthcare providers, can choose the treatment option they deem is most appropriate”.
  • ONS is proud to support the Cancer Drug Parity Act and commends the bill’s sponsors for their leadership in ensuring parity for oral cancer treatments.”
    Recognizing the pressing need for equitable access to cancer treatments, Lisa Lacasse, president of the American Cancer Society Cancer Action Network (ACS CAN), emphasized the critical issue of disparities in cost-sharing for oral chemotherapy medications.
  • For more information on the Cancer Drug Parity Act and its potential impact on cancer care, please visit https://www.access2cancercare.org/ .

TwelveStone Health Partners Infusion Services Expands to Include Innovative Cancer Treatment Medications

Retrieved on: 
Thursday, October 5, 2023
Hospital, Dawn of Destiny, Cancer, Snack, Lymphoma, ONS, Kidney, Leukemia, Lung, Oncology Nursing Society, Patient, Pharmaceutical industry, Medical imaging, Durvalumab

MURFREESBORO, Tenn. , Oct. 5, 2023 /PRNewswire-PRWeb/ -- TwelveStone Health Partners, a leading provider of comprehensive chronic care medication services, announced today an expansion of infusion services to include innovative cancer treatments at their Smyrna, Georgia infusion center with plans to also offer the specialty medications in their Murfreesboro, Tennessee location soon. As cancer medications have historically only been administered by hospitals or oncology centers, the announcement holds special significance to those suffering from the dreaded disease.

Key Points: 
  • Rollout Begins in the Smyrna, Georgia Location with Plans to Expand to Tennessee Locations
    MURFREESBORO, Tenn. , Oct. 5, 2023 /PRNewswire-PRWeb/ -- TwelveStone Health Partners, a leading provider of comprehensive chronic care medication services, announced today an expansion of infusion services to include innovative cancer treatments at their Smyrna, Georgia infusion center with plans to also offer the specialty medications in their Murfreesboro, Tennessee location soon.
  • The expansion of infusion services to include cancer treatment is possible through innovative medications like Imfinzi for lung and bladder cancer, Rituxan for lymphoma and leukemia and Opdivo for kidney and bladder cancer that are now available via infusion.
  • "These new medications offer tremendous hope for those managing a cancer diagnosis," said Shane Reeves, chief executive officer at TwelveStone.
  • Learn more about TwelveStone Health Partner's innovative infusion centers here.

The Inner Circle Acknowledges, Cassandra Mitchell as a Pinnacle Lifetime Member for her contributions to the Healthcare field

Retrieved on: 
Thursday, July 6, 2023
Theta, DNA, Organic, Society, Society of Children's Book Writers and Illustrators, Infection, Life, Face, Friends, Oncology Nursing Society, Jesus, Health care, SCBWI, Women's health, Multimedia, Continental, Medical laboratory scientist, Creativity, Morality, Lamar University, Sibling, Patient, Webster University, Physician, University, Meditation, Diagnosis, Mitchell, Stethoscope, Human resources, Family, Nationwide, Humble Boy, GO, Nursing, Science, Illustrator, Chemistry, Biology

RICHMOND, Texas, July 6, 2023 /PRNewswire/ -- Cassandra Mitchell is being recognized by Continental Who's Who as a Pinnacle Lifetime Member for her contributions to the Healthcare field.

Key Points: 
  • RICHMOND, Texas, July 6, 2023 /PRNewswire/ -- Cassandra Mitchell is being recognized by Continental Who's Who as a Pinnacle Lifetime Member for her contributions to the Healthcare field.
  • She currently works as a Clinical Implementation Manager where is responsible for providing superlative health care services to oncology patients.
  • According to Ms. Mitchell, she focuses more on behind-the-scenes of healthcare.
  • Ms. Mitchell has more than 10 years of experience in the healthcare field, having served as a Medical Technologist for five years and a Registered Nurse for ten years.

Patient & Provider Advocates Applaud Senate Reintroduction of the Cancer Drug Parity Act

Retrieved on: 
Friday, June 16, 2023
Insurance, Senate, Shoulder, Advocacy, Public policy, Oncology Nursing Society, International Myeloma Foundation, IV, Policy, Cancer, Lung cancer, Doctor of Philosophy, Senator Moran, Congress, Parity, Patient, Oral cancer, RN, Diagnosis, ONS, Legislation, Health insurance, Pharmaceutical industry

“The Cancer Drug Parity Act of 2023” will end the out-of-pocket cost disparity for orally administered cancer treatments for the approximately 110 million patients covered by federally-regulated group health plans.

Key Points: 
  • “The Cancer Drug Parity Act of 2023” will end the out-of-pocket cost disparity for orally administered cancer treatments for the approximately 110 million patients covered by federally-regulated group health plans.
  • Because of this discrepancy, patients on oral treatments can be forced to shoulder much higher out‐of‐pocket costs for their medications.
  • “The Cancer Drug Parity Act puts patients’ needs first,” said Laurie Fenton Ambrose, President & CEO, GO2 for Lung Cancer.
  • The Cancer Drug Parity Act would fix this disparity for plans regulated by the federal government.”
    Dr. Julie Gralow, Chief Medical Officer with the Association for Clinical Oncology, said, “We’ve seen tremendous progress in cancer treatments and the Cancer Drug Parity Act would protect patients’ access to the treatments their doctors prescribe.

Galera Reports First Quarter 2023 Financial Results and Recent Corporate Updates

Retrieved on: 
Thursday, May 11, 2023
AESOP, SBRT, HNC, Priority review, Otorhinolaryngology, Esophagitis, University, ARNP, Therapy, File, MSN, Oncology Nursing Society, Pharming, LAPC, Head, Survival, New Drug Application, NDA, Cancer, Lung cancer, Market access, MBA, NSCLC, Mucositis, Radiation therapy, Neck, Marketing, Sale, ASCO, SOM, Congress, Incidence, Literature, Data analysis, American Society of Clinical Oncology, Patient, Investment, Annual general meeting, PDUFA, ONS, Research, FDA, Galera, Letter, CKD, Chemoradiotherapy, Food, Society, Pharmaceutical industry, Nursing

MALVERN, Pa., May 11, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the first quarter ended March 31, 2023, and provided recent corporate updates.

Key Points: 
  • With Priority Review designation, the Prescription Drug User Fee Act (PDUFA) target date assigned by the FDA for the NDA is August 9, 2023.
  • Research and development expenses were $7.3 million in the first quarter of 2023, compared to $8.1 million for the same period in 2022.
  • As of March 31, 2023, Galera had cash, cash equivalents and short-term investments of $47.8 million.
  • Galera expects that its existing cash, cash equivalents and short-term investments will enable Galera to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2023.

Kayla A. Craig, DNP, FNP-BC, RN, is recognized by Continental Who's Who

Retrieved on: 
Thursday, December 1, 2022
Injury, Crystal, Oncology Nursing Society, Multimedia, American Nurses Association, Telemetry, Cooking, Patient, Family nurse practitioner, Nurse practitioner, American Cancer Society, American Association of Nurse Practitioners, DNP, Katie, RN, Mentorship, Continental, Medicine, Southern Illinois University

EDWARDSVILLE, Ill., Dec. 1, 2022 /PRNewswire/ -- Kayla A. Craig, DNP, FNP-BC, RN, is being recognized by Continental Who's Who as an Exceptional Healthcare Provider in the medical field for her excellence as a Family Nurse Practitioner.

Key Points: 
  • EDWARDSVILLE, Ill., Dec. 1, 2022 /PRNewswire/ -- Kayla A. Craig, DNP, FNP-BC, RN, is being recognized by Continental Who's Who as an Exceptional Healthcare Provider in the medical field for her excellence as a Family Nurse Practitioner.
  • Dr. Craig attended Southern Illinois University in Edwardsville and earned her nursing degree prior to graduating with her Doctor of Nursing Practice degree from the same academic institution.
  • She is a board-certified family nurse practitioner currently serving patients in Belleville, IL, where she specializes in urgent care practice.
  • She has experience in family medicine, pediatric home care, oncology, and telemetry.

LUNGevity Foundation's No One Missed Campaign Celebrates Second Year of #KnowYourBiomarker Storytelling Initiative to Drive Awareness of Comprehensive Biomarker Testing in Lung Cancer

Retrieved on: 
Tuesday, November 1, 2022
Amgen, Large-cell lung carcinoma, Lavern, Diagnosis, Research, Public policy, Lung cancer, Human, Oncology Nursing Society, AbbVie, Strathcona County, EML4-ALK positive lung cancer, Charity Navigator, NSCLC, Caregiver, CEO, Daiichi Sankyo, AJ, No One, Merck & Co., University, CT, Learning, Pfizer, Patient, Multimedia, Health equity, Neoplasm, ROS1, Awareness, International Association, Crusades, Conference, Cancer, Oncology, Time, AstraZeneca, Hoffmann-La Roche, Genentech, Treatment, Mentorship, Thermo Fisher Scientific, Regeneron Pharmaceuticals, Helpline, Hope, Social media, Philosophy, Clinical trial, Mutation, Quality of life, Pharmaceutical industry, Medical imaging, Sanofi

WASHINGTON, Nov. 1, 2022 /PRNewswire/ -- LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit organization, today celebrates the second year of its #KnowYourBiomarker social media initiative as part of the No One Missed campaign aimed at driving awareness of comprehensive biomarker testing in non-small cell lung cancer (NSCLC).

Key Points: 
  • "Time and time again, we've heard stories from people living with lung cancer about the difference comprehensive biomarker testing has made for their treatment journey," said Andrea Ferris, president and CEO of LUNGevity Foundation.
  • Here are two examples of people living with lung cancer who shared their biomarker testing experiences as part of the #KnowYourBiomarker initiative.
  • This is a philosophy she applied when faced with a stage IV lung cancer diagnosis in 2018 at age 52.
  • LUNGevity Foundation is the nation's leading lung cancer organization focused on improving outcomes for people with lung cancer.

HOPA Oncology Pharmacists Provide Chemotherapy Resources to Improve Patient Understanding and Outcomes

Retrieved on: 
Saturday, September 4, 2021
Health sciences, Health, Oncology, Medicinal chemistry, Pharmacy, Symbols, Pharmacist, Oncology Nursing Society, Oncology nursing

Oncology pharmacists are encouraged to use the education sheets in discussions with those undergoing cancer treatment and their caregivers.

Key Points: 
  • Oncology pharmacists are encouraged to use the education sheets in discussions with those undergoing cancer treatment and their caregivers.
  • The website is a joint effort dedicated to being forward-thinking and providing thorough education resources to improve treatment outcomes.
  • Oncology professionals and caregivers can download several IVE sheets from the site's library, which will continue to be updated by the collaborative.
  • The Hematology/Oncology Pharmacy Association (HOPA) supports hematology/oncology pharmacy professionals and promotes the role of the pharmacist in collaborative cancer care.